A5041015630- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Cancer Research and Treatments
- Immune Cell Function and Interaction
- Malaria Research and Control
- Viral Infectious Diseases and Gene Expression in Insects
- Urinary Bladder and Prostate Research
- Hip and Femur Fractures
- T-cell and B-cell Immunology
- RNA and protein synthesis mechanisms
- Trauma and Emergency Care Studies
- SARS-CoV-2 and COVID-19 Research
- Trypanosoma species research and implications
- Cytokine Signaling Pathways and Interactions
- Metabolomics and Mass Spectrometry Studies
- 14-3-3 protein interactions
- Viral Infections and Outbreaks Research
- Pelvic and Acetabular Injuries
- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- Urinary Tract Infections Management
- Steroid Chemistry and Biochemistry
- Pelvic floor disorders treatments
- Biochemical and Molecular Research
Thomas Jefferson University
2016-2019
Columbia University Irving Medical Center
2017
Columbia University
2015
Loyola University Medical Center
2008
MMV390048, a member of new class inhibitors the Plasmodium phosphatidylinositol 4-kinase, shows potential for both treatment and prophylaxis.
Abstract One major hurdle to the success of adoptive T-cell therapy is identification antigens that permit effective targeting tumors in absence toxicities essential organs. Previous work has demonstrated T cells engineered express chimeric antigen receptors (CAR-T cells) murine homolog colorectal cancer GUCY2C treat established metastases, without toxicity normal GUCY2C-expressing intestinal epithelium, reflecting structural compartmentalization endogenous apical membranes comprising lumen....
Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in 2012 and is a highly pathogenic virus. There are no treatment options against MERS-CoV for humans or animals, there large-scale clinical trials therapies MERS-CoV. To address this need, we developed an inactivated rabies virus (RABV) that contains the spike (S) protein expressed on its surface. Our initial recombinant vaccine, BNSP333-S, expresses full-length wild-type S protein; however, it showed significantly reduced viral...
Adoptive T-cell therapy (ACT) is an emerging paradigm in which T cells are genetically modified to target cancer-associated antigens and eradicate tumors. However, challenges treating epithelial cancers with ACT reflect antigen targets that not tumor-specific, permitting immune damage normal tissues, preclinical testing artificial xenogeneic models, preventing prediction of toxicities patients. In context, mucosa-restricted expressed by exploit anatomical compartmentalization shields mucosae...
<h3>Background</h3> The colorectal cancer antigen GUCY2C exhibits unique split tolerance, evoking antigen-specific CD8<sup>+</sup>, but not CD4<sup>+</sup>, T-cell responses that deliver anti-tumor immunity without autoimmunity in mice. Here, the vaccine Ad5-GUCY2C-PADRE was evaluated a first-in-man phase I clinical study of patients with early-stage to assess its safety and immunological efficacy. <h3>Methods</h3> Ten surgically-resected stage or II (pN0) colon received single intramuscular...
Characterizing self-tolerance mechanisms and their failure is critical to understand immune homeostasis, cancer immunity, autoimmunity. However, examination of has relied primarily on transgenic mice expressing TCRs targeting well-characterized, but nonphysiologic, model Ags, such as OVA hemagglutinin. Identifying directed against bona fide self-antigens made difficult by the extraordinary diversity low prevalence Ag-specific clones (<10-100 naive cells per organism), limiting dissection...
Cancer immunotherapeutics focus primarily on stimulating the immune system to elicit endogenous responses fight cancer or transferring primed effectors in adoptive cell transfer (ACT) paradigms (1,2). CD8 + T cells are desirable cancer, however, their antitumor activity is often attenuated by tolerance mechanisms suppressive nature of tumor microenvironment (3). As such, goal immunotherapies increasingly focusing overcoming barrier enhancing antigen reactivity and effector function...
<p>Figure S2 shows the scFv sequences used in paper.</p>
<p>Figure S10 shows hGUCY2C-specific activation marker upregulation, cytokine production, and lysis by human T cells expressing 5F9.h28BBz.</p>
<p>Figure S1 shows the codon-optimized sequence of human GUCY2C.</p>
<p>Figure S7 shows cytokine production by 5F9.m28BBz CAR-T cells stimulated CT26.hGUCY2C cells.</p>
<p>Figure S4 shows the human CAR construct sequence used in paper.</p>
<p>Figure S3 shows the murine CAR construct sequence used in paper.</p>
<p>Figure S11 shows that hGUCY2C-specific 5F9.m28BBz CAR-T cells do not recognize murine GUCY2C.</p>
<p>Figure S5 shows detection of 5F9.m28BBz CAR surface expression by soluble GUCY2C binding.</p>
<p>Figure S9 shows that 5F9.m28BBz CAR-T cells do not kill hGUCY2C-deficient human colorectal cancer cells.</p>
<p>Figure S8 shows killing of CT26.hGUCY2C cells by 5F9.m28BBz CAR-T β-galactosidase-release assay.</p>
<p>Figure S6 shows activation marker upregulation by 5F9.m28BBz CAR-T cells stimulated CT26.hGUCY2C cells.</p>
<div>Abstract<p>One major hurdle to the success of adoptive T-cell therapy is identification antigens that permit effective targeting tumors in absence toxicities essential organs. Previous work has demonstrated T cells engineered express chimeric antigen receptors (CAR-T cells) murine homolog colorectal cancer GUCY2C treat established metastases, without toxicity normal GUCY2C-expressing intestinal epithelium, reflecting structural compartmentalization endogenous apical...